UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of oncology, ISSN 0923-7534, 10/2017, Volume 28 Suppl 9, p. ix23
Journal Article
Gan to kagaku ryoho, ISSN 0385-0684, 12/2020, Volume 47, Issue 12, p. 1673
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Estradiol - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Mutation | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Breast cancer | Metastasis | Hormones | Research | Antineoplastic agents | Epidemiology | Antimitotic agents | Analysis | Product development | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Internationality | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Quinolines - adverse effects | Antimitotic agents | Tyrosine | Medical colleges | Care and treatment | Adjuvant treatment | Clinical trials | Product development | Breast cancer | Metastasis | College teachers | Antineoplastic agents | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 523 - 533
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Young Adult | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Chemotherapy, Adjuvant | Genes, BRCA1 | Kaplan-Meier Estimate | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Disease-Free Survival | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Phthalazines - adverse effects | Treatment outcome | Gene mutations | Analysis | Breast cancer | Genetic aspects | Research | Drug therapy | Medical research | Adenosine | Inhibitor drugs | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ribose | Medical prognosis | Risk assessment | Antitumor activity | Mutation | Drug dosages | Deoxyribonucleic acid--DNA | Vinorelbine | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 580 - 591
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Everolimus | Trastuzumab | Drug Resistance, Neoplasm - drug effects | Clinical trials | Breast cancer | Angiogenesis inhibitors | Analysis | Index Medicus
Journal Article
Surgery Today, ISSN 0941-1291, 6/2016, Volume 46, Issue 6, pp. 668 - 685
Clavien-Dindo classification | Medicine & Public Health | Surgical Oncology | Surgery | JCOG postoperative complications criteria (JCOG PC criteria) | Postoperative complications | Life Sciences & Biomedicine | Science & Technology | Complications and side effects | Complications | Index Medicus | Original
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 20, pp. 1926 - 1936
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Humans | Middle Aged | Estradiol - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Fulvestrant | Protein Kinase Inhibitors - administration & dosage | Receptors, Steroid - analysis | Pyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Estradiol - adverse effects | Breast Neoplasms - mortality | Female | Aged | ErbB Receptors - analysis | Cancer patients | Safety and security measures | Breast cancer | Dosage and administration | Drug therapy | Health aspects | Medical research | Statistical analysis | Cyclin-dependent kinases | Endocrine therapy | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Cyclin-dependent kinase 4 | Metastases | Chemotherapy | Epidermal growth factor | Womens health | Medical prognosis | Mutation | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Breast Neoplasms - surgery | Goserelin - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Premenopause | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Neoplasms, Hormone-Dependent - drug therapy | Neoplasm Staging | Nitriles - adverse effects | Antimitotic agents | Menopause | Clinical trials | Product development | Breast cancer | Postmenopausal women | Tamoxifen | Antineoplastic agents | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Humans | Middle Aged | Triple Negative Breast Neoplasms - mortality | Capecitabine - therapeutic use | Hand-Foot Syndrome - etiology | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Preoperative Care | Antimetabolites, Antineoplastic - therapeutic use | Capecitabine - adverse effects | Chemotherapy, Adjuvant - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 | Neoplasm Staging | Care and treatment | Usage | Chemotherapy | Breast cancer | Capecitabine | Cancer | Medical research | Prognosis | Invasiveness | Clinical trials | Survival | ErbB-2 protein | Feet | Epidermal growth factor | Anthracycline | Medical prognosis | Death | Index Medicus | Abridged Index Medicus
Journal Article